Cargando…
Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts
OBJECTIVES: To investigate the prevalence of comorbidities in early rheumatoid arthritis (ERA) and early axial spondyloarthritis (ESpA) versus the general population. METHODS: Baseline data of 689 patients with ERA from the Etude et Suivi des Polyarthrites Indifférenciées Récentes (ESPOIR) cohort (a...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623372/ https://www.ncbi.nlm.nih.gov/pubmed/26535145 http://dx.doi.org/10.1136/rmdopen-2015-000128 |
_version_ | 1782397675503616000 |
---|---|
author | Gherghe, Ana Maria Dougados, Maxime Combe, Bernard Landewé, Robert Mihai, Carina Berenbaum, Francis Mariette, Xavier Wolterbeek, Ron van der Heijde, Désirée |
author_facet | Gherghe, Ana Maria Dougados, Maxime Combe, Bernard Landewé, Robert Mihai, Carina Berenbaum, Francis Mariette, Xavier Wolterbeek, Ron van der Heijde, Désirée |
author_sort | Gherghe, Ana Maria |
collection | PubMed |
description | OBJECTIVES: To investigate the prevalence of comorbidities in early rheumatoid arthritis (ERA) and early axial spondyloarthritis (ESpA) versus the general population. METHODS: Baseline data of 689 patients with ERA from the Etude et Suivi des Polyarthrites Indifférenciées Récentes (ESPOIR) cohort (age 48.2±12.1 years, symptoms duration 14.2±14.5 weeks) and 645 patients with ESpA from Devenir des Spondylarthropathies Indifférenciées Récentes (DESIR; age 32.8±8.4 years, axial symptoms duration 79.0±45.7 weeks) were analysed. Metabolic and cardiovascular diseases (CVD), infections and neoplasia were determined in each cohort. The prevalence (95% CI) of several comorbidities was compared with that in the French general population. For patients without CVD, the 10-year risk of developing CVD was calculated using the Framingham and SCORE equations. The heart age was calculated using the 2008 Framingham points system. RESULTS: 42% of patients with ERA and 20.3% of patients with ESpA had at least 1 comorbidity; the most common were arterial hypertension (AHT) and dyslipidaemia. AHT prevalence (95% CI) in ERA (18.2% (15.5% to 21.3%)), but not in ESpA (5.08% (3.57% to 7.14%)), was significantly increased (p<0.05) compared with the general population (7.58%). Prevalence of tuberculosis history was higher in ERA (4.7% (3.3% to 6.6%)), and ESpA (0.99% (0.4% to 2.3%)) than in the general population (0.02%; both p<0.05). No differences were observed in malignancies, coronary heart disease or diabetes. In ERA, among patients without a history of CVD, an intermediate to high CVD risk was found. The heart age exceeded the real age by 4.1±9.6 years in ERA and by 2.1±7.0 years in ESpA (p<0.001). CONCLUSIONS: We found an increased prevalence of AHT and tuberculosis history in ERA and ESpA, and an increased CVD risk. These results should prompt rheumatologists to check these comorbidities early in the disease. |
format | Online Article Text |
id | pubmed-4623372 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-46233722015-11-03 Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts Gherghe, Ana Maria Dougados, Maxime Combe, Bernard Landewé, Robert Mihai, Carina Berenbaum, Francis Mariette, Xavier Wolterbeek, Ron van der Heijde, Désirée RMD Open Epidemiology OBJECTIVES: To investigate the prevalence of comorbidities in early rheumatoid arthritis (ERA) and early axial spondyloarthritis (ESpA) versus the general population. METHODS: Baseline data of 689 patients with ERA from the Etude et Suivi des Polyarthrites Indifférenciées Récentes (ESPOIR) cohort (age 48.2±12.1 years, symptoms duration 14.2±14.5 weeks) and 645 patients with ESpA from Devenir des Spondylarthropathies Indifférenciées Récentes (DESIR; age 32.8±8.4 years, axial symptoms duration 79.0±45.7 weeks) were analysed. Metabolic and cardiovascular diseases (CVD), infections and neoplasia were determined in each cohort. The prevalence (95% CI) of several comorbidities was compared with that in the French general population. For patients without CVD, the 10-year risk of developing CVD was calculated using the Framingham and SCORE equations. The heart age was calculated using the 2008 Framingham points system. RESULTS: 42% of patients with ERA and 20.3% of patients with ESpA had at least 1 comorbidity; the most common were arterial hypertension (AHT) and dyslipidaemia. AHT prevalence (95% CI) in ERA (18.2% (15.5% to 21.3%)), but not in ESpA (5.08% (3.57% to 7.14%)), was significantly increased (p<0.05) compared with the general population (7.58%). Prevalence of tuberculosis history was higher in ERA (4.7% (3.3% to 6.6%)), and ESpA (0.99% (0.4% to 2.3%)) than in the general population (0.02%; both p<0.05). No differences were observed in malignancies, coronary heart disease or diabetes. In ERA, among patients without a history of CVD, an intermediate to high CVD risk was found. The heart age exceeded the real age by 4.1±9.6 years in ERA and by 2.1±7.0 years in ESpA (p<0.001). CONCLUSIONS: We found an increased prevalence of AHT and tuberculosis history in ERA and ESpA, and an increased CVD risk. These results should prompt rheumatologists to check these comorbidities early in the disease. BMJ Publishing Group 2015-09-14 /pmc/articles/PMC4623372/ /pubmed/26535145 http://dx.doi.org/10.1136/rmdopen-2015-000128 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Epidemiology Gherghe, Ana Maria Dougados, Maxime Combe, Bernard Landewé, Robert Mihai, Carina Berenbaum, Francis Mariette, Xavier Wolterbeek, Ron van der Heijde, Désirée Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts |
title | Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts |
title_full | Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts |
title_fullStr | Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts |
title_full_unstemmed | Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts |
title_short | Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts |
title_sort | cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the espoir and desir cohorts |
topic | Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623372/ https://www.ncbi.nlm.nih.gov/pubmed/26535145 http://dx.doi.org/10.1136/rmdopen-2015-000128 |
work_keys_str_mv | AT ghergheanamaria cardiovascularandselectedcomorbiditiesinearlyarthritisandearlyspondyloarthritisacomparativestudyresultsfromtheespoiranddesircohorts AT dougadosmaxime cardiovascularandselectedcomorbiditiesinearlyarthritisandearlyspondyloarthritisacomparativestudyresultsfromtheespoiranddesircohorts AT combebernard cardiovascularandselectedcomorbiditiesinearlyarthritisandearlyspondyloarthritisacomparativestudyresultsfromtheespoiranddesircohorts AT landewerobert cardiovascularandselectedcomorbiditiesinearlyarthritisandearlyspondyloarthritisacomparativestudyresultsfromtheespoiranddesircohorts AT mihaicarina cardiovascularandselectedcomorbiditiesinearlyarthritisandearlyspondyloarthritisacomparativestudyresultsfromtheespoiranddesircohorts AT berenbaumfrancis cardiovascularandselectedcomorbiditiesinearlyarthritisandearlyspondyloarthritisacomparativestudyresultsfromtheespoiranddesircohorts AT mariettexavier cardiovascularandselectedcomorbiditiesinearlyarthritisandearlyspondyloarthritisacomparativestudyresultsfromtheespoiranddesircohorts AT wolterbeekron cardiovascularandselectedcomorbiditiesinearlyarthritisandearlyspondyloarthritisacomparativestudyresultsfromtheespoiranddesircohorts AT vanderheijdedesiree cardiovascularandselectedcomorbiditiesinearlyarthritisandearlyspondyloarthritisacomparativestudyresultsfromtheespoiranddesircohorts |